Skip to content

Influence of Simethicone added to the rinse water during colonoscopies on polyp-detection rates

Influence of Simethicone added to the rinse water during colonoscopies on polyp-detection rates: a cohort study utilising routine quality data

Status
Completed
Phases
Unknown
Study type
Observational
Source
ANZCTR
Registry ID
ACTRN12617001150336
Acronym
Simethicone use and polyp detection rates
Enrollment
3508
Registered
2017-08-07
Start date
2016-05-29
Completion date
2017-07-03
Last updated
2017-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The effects of simethicone added to the rinse solution during colonoscopies as antifoaming agent with regard to polyp detection rates is poorly studied. We thus aim to quantitate the effects of simethicone during a cohort study when for a defined time period the practice to routinely add simethicone to the rinse solution was discontinued and later re-introduced. Since this change was not communicated to endoscopists they were blinded with regard to this change.

Interventions

The effect of adding simethicone to the rinse solution used during routine colonoscopies was studied in a cohort study. Simethicone (approx 50 mg/100 cc) was added to the rinse solution. The rinse solution consists of pharmaceutical grade sterile water and is used to clean the lense of the endoscope and flush material from the surface of mucosa. Medical record review of procedures was performed for a 5 day period from 29 May 2017 to 2 June 2017 when Simethicone was discontinued. Medical record r

The effect of adding simethicone to the rinse solution used during routine colonoscopies was studied in a cohort study. Simethicone (approx 50 mg/100 cc) was added to the rinse solution. The rinse solution consists of pharmaceutical grade sterile water and is used to clean the lense of the endoscope and flush material from the surface of mucosa. Medical record review of procedures was performed for a 5 day period from 29 May 2017 to 2 June 2017 when Simethicone was discontinued. Medical record review of procedures was also performed from 28 May 2016 to 28 May 2017 (12 months prior to discontinuation) and from 3 June 2017 to 8 July 2017 (5 weeks following re-introduction).

Sponsors

Princess Alexandra Hospital, Brisbane
Lead SponsorHospital

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Consecutive patients undergoing colonoscopy during a 12 month time period from 29 May 2016 till 28 May 2017, for 5 days between 29 May 2017 and 2 June 2017 and for 5 weeks from 2 3 June 2017 until 8 July 2017 at the Department of Gastroenterology at the Princess Alexandra Hospital.

Exclusion criteria

emergency procedures

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026